KR102469550B1 - Cosmetic composition with uv protection, whitening and wrinkle improvement effects - Google Patents
Cosmetic composition with uv protection, whitening and wrinkle improvement effects Download PDFInfo
- Publication number
- KR102469550B1 KR102469550B1 KR1020220120067A KR20220120067A KR102469550B1 KR 102469550 B1 KR102469550 B1 KR 102469550B1 KR 1020220120067 A KR1020220120067 A KR 1020220120067A KR 20220120067 A KR20220120067 A KR 20220120067A KR 102469550 B1 KR102469550 B1 KR 102469550B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- skin
- oil
- cosmetic composition
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000000694 effects Effects 0.000 title claims abstract description 46
- 230000002087 whitening effect Effects 0.000 title claims abstract description 30
- 230000006750 UV protection Effects 0.000 title claims abstract description 19
- 230000006872 improvement Effects 0.000 title claims description 35
- 230000037303 wrinkles Effects 0.000 title claims description 28
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 50
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 50
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 27
- 239000011570 nicotinamide Substances 0.000 claims abstract description 27
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 27
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 25
- 229960005305 adenosine Drugs 0.000 claims abstract description 25
- 239000011787 zinc oxide Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 229960001296 zinc oxide Drugs 0.000 claims abstract description 10
- 230000001153 anti-wrinkle effect Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 244000179886 Moringa oleifera Species 0.000 claims description 25
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 235000005638 Austrian pine Nutrition 0.000 claims description 21
- 235000008565 Pinus banksiana Nutrition 0.000 claims description 21
- 244000019397 Pinus jeffreyi Species 0.000 claims description 21
- 235000013264 Pinus jeffreyi Nutrition 0.000 claims description 21
- 235000008578 Pinus strobus Nutrition 0.000 claims description 21
- 235000008585 Pinus thunbergii Nutrition 0.000 claims description 21
- 235000014030 Podocarpus spicatus Nutrition 0.000 claims description 21
- 235000017985 rocky mountain lodgepole pine Nutrition 0.000 claims description 21
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 20
- 239000010659 mugwort oil Substances 0.000 claims description 18
- 241000972773 Aulopiformes Species 0.000 claims description 15
- 235000019515 salmon Nutrition 0.000 claims description 15
- 239000008213 purified water Substances 0.000 claims description 14
- 210000001550 testis Anatomy 0.000 claims description 13
- 235000019493 Macadamia oil Nutrition 0.000 claims description 11
- 239000010469 macadamia oil Substances 0.000 claims description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 11
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 10
- 229960000458 allantoin Drugs 0.000 claims description 10
- 229940059958 centella asiatica extract Drugs 0.000 claims description 10
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 10
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 9
- 239000010495 camellia oil Substances 0.000 claims description 9
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 9
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 9
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 9
- 240000006891 Artemisia vulgaris Species 0.000 abstract description 9
- 230000036559 skin health Effects 0.000 abstract description 5
- 235000004355 Artemisia lactiflora Nutrition 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 64
- 230000000052 comparative effect Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 24
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 22
- 235000011613 Pinus brutia Nutrition 0.000 description 22
- 241000018646 Pinus brutia Species 0.000 description 22
- 239000003921 oil Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 12
- 230000032683 aging Effects 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- -1 lipid peroxides Chemical class 0.000 description 9
- 230000009759 skin aging Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940106189 ceramide Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000516 sunscreening agent Substances 0.000 description 8
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 7
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 230000000475 sunscreen effect Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- PLQMEXSCSAIXGB-SAXRGWBVSA-N Arteannuic acid Natural products C1=C(C)CC[C@H]2[C@H](C)CC[C@@H](C(=C)C(O)=O)[C@H]21 PLQMEXSCSAIXGB-SAXRGWBVSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000208467 Macadamia Species 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- IFYVAPPYWOMVDP-ZDUSSCGKSA-N 3-[[(2r)-2,4-diacetyloxy-3,3-dimethylbutanoyl]amino]propyl acetate Chemical compound CC(=O)OCCCNC(=O)[C@H](OC(C)=O)C(C)(C)COC(C)=O IFYVAPPYWOMVDP-ZDUSSCGKSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 240000001548 Camellia japonica Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 208000002141 Pellagra Diseases 0.000 description 2
- AJFWREUFUPEYII-UHFFFAOYSA-N Phosphatidylserin Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC([NH3+])C([O-])=O)OC(=O)CCCCCCCC=CCCCCCCCC AJFWREUFUPEYII-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- PLQMEXSCSAIXGB-UHFFFAOYSA-N artemisininic acid Natural products C1=C(C)CCC2C(C)CCC(C(=C)C(O)=O)C21 PLQMEXSCSAIXGB-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006355 external stress Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102100038341 Blood group Rh(CE) polypeptide Human genes 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 240000006055 Dacrydium cupressinum Species 0.000 description 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000666610 Homo sapiens Blood group Rh(CE) polypeptide Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000220214 Moringaceae Species 0.000 description 1
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 1
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
- KZTJQXAANJHSCE-OIDHKYIRSA-N N-octodecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC KZTJQXAANJHSCE-OIDHKYIRSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000013697 Pinus resinosa Nutrition 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- GCDXVKZXCQGDHC-BLCQCPAESA-N [30-oxo-30-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC GCDXVKZXCQGDHC-BLCQCPAESA-N 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- LZMOBPWDHUQTKL-RWMBFGLXSA-N artemisinic acid Natural products CC1=C[C@@H]2[C@@H](CCC[C@H]2C(=C)C(=O)O)CC1 LZMOBPWDHUQTKL-RWMBFGLXSA-N 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940086668 ceramide eop Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- QMHBZWNZCSNBGU-UHFFFAOYSA-N nonane-1,2,3-triol Chemical compound CCCCCCC(O)C(O)CO QMHBZWNZCSNBGU-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000037316 sun-exposed skin Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물에 관한 것으로서, 더욱 상세하게는 징크옥사이드, 나이아신아마이드, 아데노신 및 불가리스 쑥 오일을 유효성분으로 포함하는 화장료 조성물을 구성함으로써, 자외선 차단, 미백, 피부주름개선 및 피부장벽 개선 효과가 우수하고 피부의 건강을 향상시킬 수 있는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition having sunscreen and whitening and wrinkle-improving effects, and more particularly, by constructing a cosmetic composition containing zinc oxide, niacinamide, adenosine and vulgaris mugwort oil as active ingredients, thereby providing UV protection, whitening, It relates to a cosmetic composition having excellent skin wrinkle improvement and skin barrier improvement effects and UV protection and whitening wrinkle improvement effects that can improve skin health.
현대사회는 배기가스, 유해 화학물질, 오존층의 파괴 등으로 자외선, 수질오염 등에 의한 활성산소가 대량으로 발생하고 있고, 이러한 활성산소는 인체에 침투하여 여러 가지 부작용을 일으키며, 특히 색소변화, 피부노화 등의 주요원인으로 알려지고 있다.In modern society, a large amount of active oxygen is generated due to ultraviolet rays and water pollution due to exhaust gas, harmful chemicals, and destruction of the ozone layer. These active oxygen penetrate the human body and cause various side effects, especially pigment change and skin aging. are known to be the main causes of
또한, 근래에는 과중한 사회적, 업무적 스트레스를 해소하기 위하여 골프 등과 같은 야외에서의 레저활동이 증가하고 있는데, 이러한 야외에서의 레저활동 중에는 신체 피부가 상기한 오염원 등에 더욱 쉽게 직접적으로 노출되기 때문에 피부훼손 및 피부노화를 피할 수 없는 실정이어서 야외 레저활동을 보다 적극적이고 쾌적하게 즐기고자 하는 추세에 부정적인 영향을 미치고 있다.In addition, in recent years, outdoor leisure activities such as golf are increasing in order to relieve excessive social and work stress. and skin aging are unavoidable, negatively affecting the trend to enjoy outdoor leisure activities more actively and comfortably.
일반적으로 피부는 기본적인 신진대사 과정을 통하여 우리 몸의 항상성을 저해하는 다양한 외부 요인으로부터 위해를 막아주는 일차적인 기능을 담당하고 있다. 즉, 피부는 신체 가장 바깥쪽에 위치함으로써 물리적, 화학적, 생물학적 장벽기능을 통한 보호작용, 체온조절작용, 감각작용, 분비 및 배설작용, 흡수작용, 저장작용, 재생작용 등의 다양한 역할을 수행하고 있지만, 지속적인 외부 스트레스가 가해지는 경우 가장 손상을 받기 쉽다.In general, the skin is in charge of the primary function of preventing harm from various external factors that impede the homeostasis of our body through basic metabolic processes. In other words, as the skin is located at the outermost part of the body, it performs various roles such as protection through physical, chemical, and biological barrier functions, temperature regulation, sensation, secretion and excretion, absorption, storage, and regeneration. However, it is most susceptible to damage when subjected to sustained external stress.
이러한 외부 스트레스의 주요 원인으로는 자외선 노출, 배기가스, 황사, 환경오염물, 중금속, 온도변화, 미생물을 대표적인 예로 들 수 있으며, 이들은 주로 산화적 스트레스(oxidative stress)를 통하여 활성산소종(reactive oxygen species, ROS)을 생성함으로써, 항산화 방어체계를 붕괴시켜 세포 손상 및 사멸을 야기하게 된다.Major causes of these external stresses include exposure to ultraviolet rays, exhaust gas, yellow dust, environmental pollutants, heavy metals, temperature changes, and microorganisms. These are mainly reactive oxygen species through oxidative stress. , ROS), thereby disrupting the antioxidant defense system and causing cell damage and death.
일반적으로 피부 세포의 탄력성 및 수축성이 약화하여 피부 주름살이 생기는 현상은 다양한 원인에 의해 나타나지만, 피부노화가 피부의 수축, 수렴작용을 저하시키기 때문이라는 것이 널리 알려져 있다.In general, skin wrinkles due to weakened elasticity and contractility of skin cells appear due to various causes, but it is widely known that skin aging reduces skin contraction and convergence.
이러한 피부의 노화는 크게 내부 요인적 노화(intrinsic aging)와 외부 요인적 노화(extrinsic aging)로 대별되는데, 내부 요인적 노화는 나이가 듦에 따라 피부의 생리적 기능이 점차 저하되어 자연적으로 나타나는 노화 현상으로 임상학적으로 탄력이 감소하고, 피부결이 거칠어지며, 깊은 주름이 생기고 색소가 침착되는 특징이 있다.Skin aging is largely divided into intrinsic aging and extrinsic aging. Intrinsic aging is a naturally occurring aging phenomenon in which the physiological function of the skin gradually deteriorates with age. Clinically, it is characterized by a decrease in elasticity, rough skin texture, deep wrinkles, and pigmentation.
또한, 외부 요인적 노화는 자외선, 활성산소종(reactive oxygen species) 및 스트레스 등의 외인적 요인에 의해 발생하는 노화 현상을 말한다. 이러한 요인들에 의해 피부의 노화가 급속히 진행되며, 그 결과 피부 표면에 거친 주름이 생성되고 탄력이 현저히 감소하게 된다.In addition, aging caused by external factors refers to an aging phenomenon caused by extrinsic factors such as ultraviolet rays, reactive oxygen species, and stress. Aging of the skin progresses rapidly due to these factors, and as a result, rough wrinkles are formed on the skin surface and elasticity is significantly reduced.
상기와 같은 피부의 노화 기작을 규명하기 위한 다양한 연구들이 진행되고, 이러한 연구들에 의해 여러 가지 피부 노화의 원인이 밝혀졌는데, 피부가 온도의 변화, 습도의 저하 또는 바람 등에 의해 건조하게 되면 외부에 대한 방어벽으로서의 피부 생리 활성이 저하되어 노화가 촉진되며, 유해 활성산소종 또는 자유 라디칼에 피부가 노출되면 체내의 산화 작용에 의해 과산화 지질이 생성되고 피부를 구성하는 여러가지 단백질들의 변형을 유발하게 되어 피부노화가 진행된다.Various studies have been conducted to identify the aging mechanism of the skin as described above, and various causes of skin aging have been identified through these studies. Aging is accelerated as the physiological activity of the skin as a barrier to defense decreases, and when the skin is exposed to harmful reactive oxygen species or free radicals, lipid peroxides are produced by oxidation in the body and various proteins constituting the skin are transformed, resulting in skin damage. Aging proceeds.
이러한 피부 노화와 탄력저하는 자외선 등에 의한 피부세포(섬유아세포)의 약화로 콜라겐과 엘라스틴의 생성저하 및 파괴에 의해 유발된다. 자외선 등에 의해 피부 내에 콜라게나제(Collagenase)와 엘라스타제(Elastase)가 발현되며, 이 효소는 피부내의 정상적인 콜라겐과 엘라스틴을 분해하여 피부 탄력저하를 가져온다.Such skin aging and loss of elasticity are caused by deterioration and destruction of collagen and elastin production due to weakening of skin cells (fibroblasts) by ultraviolet rays and the like. Collagenase and Elastase are expressed in the skin by ultraviolet rays, etc., and these enzymes decompose normal collagen and elastin in the skin, resulting in a decrease in skin elasticity.
한편, 현대 사회의 급속한 산업화와 더불어 오존층의 파괴는 UV 양의 증가를 유발하여 활성산소종과 같은 강력한 산화 물질들을 생성시키고 세포막 및 DNA 손상을 일으켜 피부 노화를 촉진시키고 있다. 더 나아가 활성산소종과 같은 산화물질에 대한 방어물질로 생성되는 멜라닌은 색소 침착을 유발하여 기미 주근깨 등의 원인이 되고 있으며 세포막 파괴로 인한 과산화지질 등은 피부트러블 유발 인자이기도 하다.On the other hand, the destruction of the ozone layer along with the rapid industrialization of modern society causes an increase in the amount of UV to generate strong oxidizing substances such as reactive oxygen species, and damages cell membranes and DNA, thereby accelerating skin aging. Furthermore, melanin, which is produced as a defense material against oxidants such as reactive oxygen species, induces pigmentation and causes melasma and freckles, and lipid peroxide due to cell membrane destruction is also a factor inducing skin trouble.
그러므로 항산화능은 피부를 보호하는 가장 기본이 되는 효능이기에 vitC, 토코페롤, 코엔자임 Q10과 같은 다양한 항산화제가 화장료 제조에 이용되어 다양한 산화물질들로부터 피부를 보호하는 목적으로 화장품의 재료로 사용되고 있다.Therefore, since antioxidant activity is the most basic effect of protecting the skin, various antioxidants such as vitC, tocopherol, and coenzyme Q10 are used in cosmetics manufacturing to protect the skin from various oxidants.
이에 본 발명자는 징크옥사이드, 나이아신아마이드, 아데노신, 불가리스 쑥 오일을 유효성분으로 포함하는 화장료 조성물을 구성함으로써, 자외선 차단, 미백, 피부주름개선 및 피부장벽 개선 효과가 우수하고 피부의 건강을 향상시킬 수 있음을 확인하고 본 발명을 완성하였다.Accordingly, the inventors of the present invention construct a cosmetic composition containing zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil as active ingredients, so that the effects of sunscreen, whitening, skin wrinkle improvement, and skin barrier improvement are excellent and skin health can be improved. It was confirmed that there was, and the present invention was completed.
본 발명이 해결하고자 하는 과제는, 징크옥사이드, 나이아신아마이드, 아데노신 및 불가리스 쑥 오일을 유효성분으로 포함하는 화장료 조성물을 구성함으로써, 자외선 차단, 미백, 피부주름개선 및 피부장벽 개선 효과가 우수하고 피부의 건강을 향상시킬 수 있는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물을 제공하는데 있다.The problem to be solved by the present invention is to construct a cosmetic composition containing zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil as active ingredients, so that UV protection, whitening, skin wrinkle improvement and skin barrier improvement effects are excellent, and the skin It is to provide a cosmetic composition having UV protection and whitening and anti-wrinkle effects that can improve health.
또한, 본 발명이 해결하고자 하는 다른 과제는, 피부 자극을 최소화하고 메마르고 건조한 피부를 촉촉하고 매끄럽게 가꾸어줄 수 있으며 우수한 피부 흡수 효과가 장시간 지속되고 화장료의 제형 안정성이 우수한 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물을 제공하는데 있다.In addition, another problem to be solved by the present invention is to minimize skin irritation, to make dry and dry skin moist and smooth, to have excellent skin absorption effect lasting for a long time, to have excellent formulation stability of cosmetics, to have excellent UV protection and whitening wrinkle improvement effect It is to provide a cosmetic composition with.
본 발명이 해결하고자 하는 다양한 과제들은 이상에서 언급한 과제들에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.Various problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
본 발명의 기술적 사상의 일 실시예에서는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물을 개시한다.In one embodiment of the technical idea of the present invention, a cosmetic composition having UV protection and whitening and anti-wrinkle effects is disclosed.
상기 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은 징크옥사이드, 나이아신아마이드, 아데노신 및 불가리스 쑥 오일을 유효성분으로 포함하고, 상기 징크옥사이드 1 내지 5 중량%, 나이아신아마이드 2 내지 5 중량%, 아데노신 0.01 내지 0.1 중량% 및 불가리스 쑥 오일 2 내지 6 중량%의 중량 비율로 포함될 수 있다.The cosmetic composition having sunscreen and whitening and wrinkle-improving effects includes zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil as active ingredients, and 1 to 5% by weight of the zinc oxide, 2 to 5% by weight of niacinamide, and 0.01 adenosine to 0.1% by weight and 2 to 6% by weight of vulgaris mugwort oil.
기타 실시예들의 구체적인 사항들은 상세한 설명에 포함되어 있다.Details of other embodiments are included in the detailed description.
본 발명의 기술적 사상의 다양한 실시예에 의한 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은, 징크옥사이드, 나이아신아마이드, 아데노신 및 불가리스 쑥 오일을 유효성분으로 포함함으로써, 자외선 차단, 미백, 피부주름개선 및 피부장벽 개선 효과가 우수하고 피부의 건강을 향상시킬 수 있다.The cosmetic composition having sunscreen and whitening and wrinkle-improving effects according to various embodiments of the technical concept of the present invention contains zinc oxide, niacinamide, adenosine and vulgaris mugwort oil as active ingredients, thereby blocking ultraviolet rays, whitening, and improving skin wrinkles And it is excellent in skin barrier improvement effect and can improve skin health.
또한, 본 발명의 기술적 사상의 다양한 실시예에 의한 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은, 피부 자극을 최소화하고 메마르고 건조한 피부를 촉촉하고 매끄럽게 가꾸어줄 수 있으며 우수한 피부 흡수 효과가 장시간 지속되고 화장료의 제형 안정성이 우수하다.In addition, the cosmetic composition having UV protection and whitening and wrinkle improvement effects according to various embodiments of the technical idea of the present invention can minimize skin irritation, make dry and dry skin moist and smooth, and has an excellent skin absorption effect that lasts for a long time The formulation stability of cosmetics is excellent.
본 발명의 기술적 사상의 다양한 실시예는, 구체적으로 언급되지 않은 다양한 효과를 제공할 수 있다는 것이 충분히 이해될 수 있을 것이다.It will be fully understood that various embodiments of the technical idea of the present invention can provide various effects not specifically mentioned.
도 1은 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물의 피부 밝기 개선 효과를 보여주는 그래프이다.
도 2는 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1 내지 4에 따른 화장료 조성물의 피부 주름 개선 효과를 보여주는 그래프이다.1 is a graph showing the skin brightness improvement effect of the cosmetic compositions according to Examples 1, 2 and 3 and the cosmetic compositions according to Comparative Examples 1 and 2.
Figure 2 is a graph showing the skin wrinkle improvement effect of the cosmetic compositions according to Examples 1, 2, and 3 and the cosmetic compositions according to Comparative Examples 1 to 4.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예를 참조하면 명확해질 것이다. 그러나 본 발명은 여기서 설명되는 실시예들에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 실시예들은 개시된 내용이 철저하고 완전해질 수 있도록 그리고 당업자에게 본 발명의 사상이 충분히 전달될 수 있도록 하기 위해 제공되는 것이다.The advantages and features of the present invention, and how to achieve them, will become clear with reference to the detailed description of the embodiments below. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the embodiments introduced herein are provided so that the disclosed content will be thorough and complete and the spirit of the present invention will be sufficiently conveyed to those skilled in the art.
본 출원에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다.Terms used in this application are only used to describe specific embodiments, and are not intended to limit the present invention. Singular expressions include plural expressions unless the context clearly dictates otherwise.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미가 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미가 있는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having meanings consistent with the meanings in the context of the related art, and unless explicitly defined in this application, they should not be interpreted in ideal or excessively formal meanings. don't
이하, 본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물에 대하여 바람직한 실시예를 들어 상세하게 설명한다.Hereinafter, a cosmetic composition having UV protection and whitening and anti-wrinkle effects according to an embodiment of the technical idea of the present invention will be described in detail with a preferred embodiment.
본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은 징크옥사이드, 나이아신아마이드, 아데노신 및 불가리스 쑥 오일을 유효성분으로 포함한다.According to one embodiment of the technical concept of the present invention, the cosmetic composition having sunscreen and whitening and wrinkle-improving effects includes zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil as active ingredients.
또한, 본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은 징크옥사이드 1 내지 5 중량%, 나이아신아마이드 2 내지 5 중량%, 아데노신 0.01 내지 0.1 중량% 및 불가리스 쑥 오일 2 내지 6 중량%의 중량 비율로 포함될 수 있다.In addition, the cosmetic composition having sunscreen and whitening and wrinkle-improving effects according to an embodiment of the technical idea of the present invention contains 1 to 5% by weight of zinc oxide, 2 to 5% by weight of niacinamide, 0.01 to 0.1% by weight of adenosine and vulgaris mugwort. Oil may be included in a weight ratio of 2 to 6% by weight.
상기 징크옥사이드는 징크옥사이드는 천연상태에서 징카이드라는 광석을 연소 및 가열하여 정제한 분말로 만든 산소와 아연의 화합물로서 물에 용해되지 않으며 백색을 띠는 무기산화물(산화아연) 비활성 미네랄 성분으로 흔히 농축제, 미백제, 윤활제, 선스크린제로 사용되는 성분이다.The zinc oxide is a compound of oxygen and zinc made from powder purified by burning and heating an ore called zinc oxide in a natural state. It is insoluble in water and is a white inorganic oxide (zinc oxide) inactive mineral component. It is often used as a thickening agent, whitening agent, lubricant, and sunscreen agent.
상기 징크옥사이드는 태양광을 반사시킴으로서 UVA와 UVB를 동시에 차단시키며, 가시광선을 산란시켜주어 피부 세포 손상을 막아주고 피부 노화를 예방시켜주는 기능이 있다. 피부에 사용시 즉각적인 차단효과가 있으며 화학적 자외선 차단제에 비해 안정적으로 사용할 수 있다는 장점이 있다.The zinc oxide blocks UVA and UVB at the same time by reflecting sunlight, and has a function of preventing skin cell damage and preventing skin aging by scattering visible rays. When used on the skin, it has an immediate blocking effect and has the advantage of being more stable than chemical sunscreens.
상기 나이아신아마이드는 비타민 B 복합체로 인체에 필수적으로 필요한 요소이면서 녹색 채소나 곡류 등 식품에 포함되어 있다. 또한, 열과 빛에 안정하여 화장품에 사용하기 적합한 성분이다. 상기 나이아신아마이드는 수용성 비타민 B3 또는 비타민 PP로 알려져 있다. 식품에서는 비타민 그 자체 또는 트립토판으로 존재할 수 있는데, 이때 60mg의 트립토판은 나이아신아마이드 1mg으로 전환된다.Niacinamide is a vitamin B complex that is essential to the human body and is included in foods such as green vegetables and grains. In addition, it is stable to heat and light and is suitable for use in cosmetics. The niacinamide is known as water-soluble vitamin B3 or vitamin PP. In foods, it can be present as the vitamin itself or as tryptophan, where 60 mg of tryptophan is converted to 1 mg of niacinamide.
상기 나이아신아마이드는 피부건강 및 정신건강, 세포의 에너지 재생 촉진과 소화기관을 건강하게 도와준다. 상기 나이아신아마이드의 흡수가 부족하여 펠라그라(pellagra) 또는 홍반병으로 불리는 비타민 결핍증에 걸릴 수 있다. 펠라그라는 햇빛에 노출된 피부의 염증(pigmented rash), 소화관 점막의 염증, 피부암, 구토, 변비 또는 설사, 연한 홍색 혀(bright red tongue)와 같은 소화관 장애, 우울증, 무감각(apathy), 두통, 피로, 및 기억상실과 같은 신경계 장애를 나타낸다.The niacinamide promotes skin health and mental health, energy regeneration of cells, and helps keep the digestive system healthy. Lack of absorption of the niacinamide can lead to a vitamin deficiency called pellagra or erythema. Pellagra is a pigmented rash of sun-exposed skin, inflammation of the mucous membranes of the digestive tract, skin cancer, digestive tract disorders such as vomiting, constipation or diarrhea, bright red tongue, depression, apathy, headache, and fatigue. , and neurological disorders such as memory loss.
상기 나이아신아마이드 성분은 수분보유력을 높여 피부를 부드럽게 하고 피부에 볼륨감을 형성시킨다. 피부에 피부 장벽을 형성하는 지방산과 세라마이드는 피부가 수분을 잃게 되면 그 기능을 제대로 수행하지 못한다. 이때, 상기 나이아신아마이드가 피부수분을 지속시켜 피부 장벽 형성과 강화에 도움을 줄 수 있다. 또한, 멜라닌 색소 침착을 연하게 또는 억제하여 전체적인 피부톤을 균일화 시키는데 도움을 줘 피부 미백에도 효능이 있다.The niacinamide component increases moisture retention, softens the skin, and forms a sense of volume in the skin. Fatty acids and ceramides that form the skin barrier on the skin do not perform their functions properly when the skin loses moisture. At this time, the niacinamide can help to form and strengthen the skin barrier by maintaining skin moisture. In addition, it is effective in skin whitening by helping to uniformize the overall skin tone by softening or suppressing melanin pigmentation.
상기 아데노신은 백색의 침상결정이며 녹는점 235℃이고, 열이나 빛, 일광에 매우 안정한 물질로서 주름기능성 화장품 원료로 널리 사용되고 있으나, 용해도가 낮아 화장품 제형 내에서 그 효능을 충분히 나타내기 어렵다. 실온에서 물에 0.7% 녹으나, 저온에서 용해도가 매우 낮아 시간이 지나면서 석출되고, 알코올에는 거의 녹지 않기 때문에 1.0%이상을 함유하는 화장품을 찾기 어렵다.The adenosine is a white needle crystal, has a melting point of 235 ° C, is very stable to heat, light, and sunlight, and is widely used as a wrinkle functional cosmetic raw material, but has low solubility, so it is difficult to sufficiently show its efficacy in cosmetic formulations. It is 0.7% soluble in water at room temperature, but its solubility is very low at low temperatures, and it precipitates over time, and it is hardly soluble in alcohol, so it is difficult to find cosmetics containing more than 1.0%.
상기 아데노신은 세포 외부의 신호전달에 관여하는 뉴클레오사이드(necleoside)로서 피부 섬유아세포의 DNA 합성을 촉진하고 단백질 합성을 증가시키는 역할을 한다. 또한, 최근 연구에 의하면 아데노신이 탈모방지와 모발성장에 도 효과가 있다. 탈모방지 및 발모성분으로 대표적인 것에 미녹시딜(Minoxidil)이 있는데 이것과 비교하여 오히려 아데노신이 효과가 더 좋다는 보고가 있다. 미녹시딜은 탈모 및 모발 성장 효과가 있지만 호르몬 변화와 혈압 변동과 같은 부작용이 있을 수 있는데 아데노신은 알려진 부작용이 없다.The adenosine is a nucleoside involved in signal transduction outside the cell, and serves to promote DNA synthesis and increase protein synthesis in skin fibroblasts. In addition, according to a recent study, adenosine is effective in preventing hair loss and growing hair. There is a report that adenosine is rather effective compared to minoxidil (Minoxidil) as a representative ingredient for preventing hair loss and hair growth. Minoxidil has hair loss and hair growth effects, but there may be side effects such as hormonal changes and blood pressure fluctuations, but adenosine has no known side effects.
상기 불가리스 쑥 오일(Artemisia Vulgaris Oil)은 국화과에 속하는 다년생 초본식물인 불가리스 쑥에서 제조될 수 있는데, 상기 불가리스 쑥 오일에 포함된 성분인 베타-카로틴(Beta-carotene)은 활성산소에 대해 피부 보호 능력을 가지고, 발생한 활성산소를 제거하는데 관여하여 피부에 발생한 산화적 손상을 예방하는데 도움을 줄 수 있다.The vulgaris mugwort oil (Artemisia Vulgaris Oil) can be prepared from vulgaris mugwort, a perennial herbaceous plant belonging to the Asteraceae family. , it can help prevent oxidative damage to the skin by being involved in removing the generated active oxygen.
상기 불가리스 쑥에 포함된 성분으로는 알테미시닌(Artemisinin), 알테미시닌산(Artemisinic acid) 등 테르펜 화합물이 있으며, 수집종과 재배방법에 따라 불가리스 쑥에 포함된 성분의 차이가 나타난다고 보고된 바 있는데, 상기 불가리스 쑥은 기혈과 경맥을 따뜻하게 하므로 자궁과 하복부가 허약하고 차서 생기는 자궁 출혈, 임신 중 출혈, 토혈, 코피, 각혈에 지혈 반응을 나타낸다. 또한, 하초가 허약하고 차며 복부에 냉감과 동통이 있는 증상 및 생리불순, 생리통, 대하 등에 사용하며, 습진, 피부가려움증에도 효과가 있다. 약리작용으로 지혈작용, 억균작용, 기관지평활근 이완작용, 진해거담작용, 수면작용, 자궁흥분유도작용, 과민성 쇼크 보호작용 등이 있는 것으로 알려져 있다Components contained in the Bulgarian mugwort include terpene compounds such as artemisinin and artemisinic acid, and it is reported that the components contained in the Bulgarian mugwort differ depending on the collection species and cultivation method. However, since the vulgaris mugwort warms the blood and meridians, it shows a hemostatic response to uterine bleeding, bleeding during pregnancy, vomiting blood, nosebleeds, and hemoptysis caused by weak and cold uterus and lower abdomen. In addition, it is used for symptoms such as weakness and cold, cold feeling and pain in the abdomen, menstrual irregularity, dysmenorrhea, and pruritus, and is also effective for eczema and skin itching. It is known that pharmacological actions include hemostasis, antibacterial action, bronchial smooth muscle relaxation, antitussive expectoration, sleep action, uterine excitation induction, and hypersensitivity shock protection.
한편, 본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은 상기 징크옥사이드, 나이아신아마이드, 아데노신, 불가리스 쑥 오일 이외에, 복합나노리포좀, 마카다미아 오일, 모링가씨 오일, 흑솔잎발효추출액, 에탄올, 1,2-헥산디올, 병풀추출물, 알란토인, 에틸헥실글리세린, 글리세릴카프릴레이트 및 정제수를 더 포함할 수 있다.On the other hand, the cosmetic composition having UV protection and whitening and wrinkle improvement effects according to an embodiment of the technical idea of the present invention includes complex nanoliposomes, macadamia oil, and moringa seed oil in addition to the zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil. , black pine needle fermented extract, ethanol, 1,2-hexanediol, centella asiatica extract, allantoin, ethylhexyl glycerin, glyceryl caprylate and purified water may be further included.
또한, 본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물은 징크옥사이드 1 내지 5 중량%, 나이아신아마이드 2 내지 5 중량%, 아데노신 0.01 내지 0.1 중량%, 불가리스 쑥 오일 2 내지 6 중량%, 복합나노리포좀 1 내지 3 중량%, 마카다미아 오일 0.5 내지 2.5 중량%, 모링가씨 오일 0.5 내지 2.5 중량%, 흑솔잎발효추출액 0.3 내지 0.7 중량%, 에탄올 8 내지 12 중량%, 1,2-헥산디올 1 내지 3 중량%, 병풀추출물 0.1 내지 1 중량%, 알란토인 0.15 내지 0.35 중량%, 에틸헥실글리세린 1 내지 3 중량%, 글리세릴카프릴레이트 0.1 내지 1 중량% 및 잔량의 정제수를 포함할 수 있다.In addition, the cosmetic composition having UV protection and whitening and wrinkle improvement effects according to an embodiment of the technical idea of the present invention contains 1 to 5% by weight of zinc oxide, 2 to 5% by weight of niacinamide, 0.01 to 0.1% by weight of adenosine, and vulgaris mugwort. 2 to 6% by weight of oil, 1 to 3% by weight of complex nanoliposome, 0.5 to 2.5% by weight of macadamia oil, 0.5 to 2.5% by weight of moringa seed oil, 0.3 to 0.7% by weight of fermented extract of black pine needles, 8 to 12% by weight of ethanol , 1 to 3% by weight of 1,2-hexanediol, 0.1 to 1% by weight of centella asiatica extract, 0.15 to 0.35% by weight of allantoin, 1 to 3% by weight of ethylhexylglycerin, 0.1 to 1% by weight of glyceryl caprylate and the remaining amount of purified water can include
상기 복합나노리포좀은 연어정소단백질추출물과 동백오일을 포함하여 제조될 수 있는데, 상기 연어정소단백질추출물은 연어의 정소단백질로부터 유래한 추출물로서, 핵산 및 단백질을 다량 함유하고 있다. 연어정소단백질추출물의 핵산은 DNA 또는 RNA를 모두 포함하며, 단백질은 아르기닌과 같은 염기성 아미노산을 다량 함유한 염기성 단백질인데, 핵산은 세포재생, 면역기능개선, 과산화지질억제, 프로타민은 그램양성균에 대한 항미생물효과, 전자공여능이 있다고 보고 되어져 있다.The complex nanoliposome may be prepared by including salmon testis protein extract and camellia oil. The salmon testis protein extract is an extract derived from salmon testicular protein and contains a large amount of nucleic acid and protein. The nucleic acids of the salmon testis protein extract include both DNA and RNA, and the protein is a basic protein containing a large amount of basic amino acids such as arginine. It has been reported to have microbial effects and electron donating ability.
특히, 연어 정소에 많이 분포되어 있는 핵산과 프로타민은 우리 몸에 필수적인 단백질로서, 정상적인 산소대사 과정 중에 생성되는 자유라디칼로부터 세포를 지키는 항산화 효소의 중요한 구성 성분이다.In particular, nucleic acids and protamine, which are abundantly distributed in salmon testis, are essential proteins for our body and are important components of antioxidant enzymes that protect cells from free radicals generated during normal oxygen metabolism.
예를 들어, 연어정소단백질추출물에는 핵산이 다량 함유되어 있어, 피부개선 또는 면역향상에 우수한 효과를 보이는데, 구체적으로, 핵산내에 포함된 아데닐산 (AMP), 티미딜산 (TMP), 구아닐산(GMP), 시티딘일인산 (CMP) 성분은 세포의 분화 및 증식을 촉진하며, 암세포의 자살을 유도한다. 또한, 핵산은 NK세포를 활성화하여, 악성세포, 노화세포를 퇴출하고, 정상세포 생성을 촉진한다.For example, salmon testicular protein extract contains a large amount of nucleic acids, and shows excellent effects on skin improvement or immunity improvement. Specifically, adenylic acid (AMP), thymidylic acid (TMP), and guanylic acid (GMP) , Cytidine monophosphate (CMP) component promotes differentiation and proliferation of cells and induces suicide of cancer cells. In addition, nucleic acids activate NK cells, expel malignant cells and senescent cells, and promote the production of normal cells.
상기 연어정소단백질추출물은 공지의 물질로, 상기 연어 정소단백질에서 연어정소단백질추출물을 제조하는 구성은 공지의 기술인바, 설명의 편의 및 본 발명의 기술적 사상의 명확성을 위하여 이에 대한 구체적인 설명은 생략하기로 한다.The salmon testis protein extract is a known substance, and the configuration of preparing the salmon testis protein extract from the salmon testis protein is a known technique, so a detailed description thereof will be omitted for convenience of description and clarity of the technical idea of the present invention. do it with
또한, 상기 동백오일은 동백의 씨로부터 추출될 수 있는데, 동백오일은 오메가-3 지방산, 오메가-6 지방산 등의 불포화 지방산이 많이 함유되어 있는 것으로 알려져 있으며, 특히 올레익산(oleic acid)이 많이 함유되어 있을 수 있다. 상기 올레익산은 활성 산소를 제거하는데 도움을 주며, 피부 내 수분의 탈수 방지 효과, 보호막 형성과 같은 작용을 할 수 있다.In addition, the camellia oil can be extracted from the seeds of camellia. Camellia oil is known to contain a lot of unsaturated fatty acids such as omega-3 fatty acids and omega-6 fatty acids, and especially contains a lot of oleic acid. may have been The oleic acid helps to remove active oxygen, and can act as an effect of preventing dehydration of moisture in the skin and forming a protective film.
또한, 상기 동백오일은 보습 효과가 매우 뛰어나 아토피 치료에 효과적이며 탁월한 콘디셔닝 효과가 있어서 예로부터 머리카락과 피부를 가꾸는데 사용되었으며, 잘 변질되지 않고 피부에 잘 스며들어 마사지의 베이스 오일로서도 매우 뛰어나며 또한 피지의 산화를 억제하는 효과와 노화 피부·건성 피부에 많이 사용되고 있다.In addition, the camellia oil has a very excellent moisturizing effect, is effective in treating atopy, and has an excellent conditioning effect, so it has been used to care for hair and skin since ancient times. It has the effect of suppressing the oxidation of sebum and is widely used for aging skin and dry skin.
상기 복합나노리포좀은 하기의 방법으로 제조된 복합나노리포좀이 사용될 수 있다.The composite nano-liposome may be a composite nano-liposome prepared by the following method.
즉, 상기 연어정소단백질추출물과 동백오일이 유효성분으로 포함된 복합나노리포좀은, (A) 복합나노리포좀을 제조하기 위한 수상부 및 유상부의 전체 중량에 대하여, 펩타이드 혼합물 1 내지 10 중량부, 에틸헥실글리세린 8 내지 12 중량부, 연어정소단백질추출물 1 내지 10 중량부, 베헤닐알코올(Behenyl Alcohol) 1 내지 10 중량부, 1,2-부틸렌글리콜 10 내지 20 중량부, 판테닐트라이아세테이트(Panthenyl Triacetate) 3 내지 7 중량부 및 이세티오네이트 0.1 내지 1 중량부를 정제수 40 내지 60 중량부와 60 내지 70℃ 온도에서 혼합하여 수상부를 제조하는 단계;That is, the composite nanoliposome containing the salmon testis protein extract and camellia oil as active ingredients, (A) 1 to 10 parts by weight of the peptide mixture, ethyl 8 to 12 parts by weight of hexylglycerin, 1 to 10 parts by weight of salmon testis protein extract, 1 to 10 parts by weight of behenyl alcohol, 10 to 20 parts by weight of 1,2-butylene glycol, panthenyltriacetate (Panthenyl preparing an aqueous phase by mixing 3 to 7 parts by weight of triacetate and 0.1 to 1 part by weight of isethionate with 40 to 60 parts by weight of purified water at a temperature of 60 to 70 ° C;
(B) 복합나노리포좀을 제조하기 위한 수상부 및 유상부의 전체 중량에 대하여, 인지질 10 내지 20 중량부와 디메치콘 5 내지 15 중량부, 동백오일 5 내지 10 중량부, 지방산 0.5 내지 1.5 중량부, 콜레스테롤 0.5 내지 3.0 중량부, 세라마이드복합체 1 내지 10 중량부, 레시틴(Hydrogenated Lecithin) 1 내지 5 중량부 및 소듐메틸코코일타우레이트 0.1 내지 1 중량부를 60 내지 70℃ 온도에서 혼합하여 유상부를 제조하는 단계;(B) 10 to 20 parts by weight of phospholipids, 5 to 15 parts by weight of dimethicone, 5 to 10 parts by weight of camellia oil, 0.5 to 1.5 parts by weight of fatty acids, Preparing an oil phase by mixing 0.5 to 3.0 parts by weight of cholesterol, 1 to 10 parts by weight of ceramide complex, 1 to 5 parts by weight of lecithin (Hydrogenated Lecithin) and 0.1 to 1 part by weight of sodium methyl cocoyl taurate at a temperature of 60 to 70 ° C. ;
(C) 상기 (A)단계에서 제조된 수상부를 50 내지 60℃ 온도에서 가온한 후, 상기 (B) 단계에서 제조된 유상부를 첨가하여 4,000 내지 5,000 rpm으로 20 내지 40분 동안 호모믹서를 이용하여 유화시킨 뒤, 상온으로 냉각하여 마이크로플루이다이저(Microfluidizer)를 이용하여 900 내지 1,100 Bar 조건에서 3 내지 5회 투과시키는 고압 유화를 통하여 유중수형(W/O형) 복합나노리포좀을 제조하는 단계; 및(C) After heating the water phase prepared in step (A) at a temperature of 50 to 60 ° C, adding the oil phase prepared in step (B) and using a homomixer at 4,000 to 5,000 rpm for 20 to 40 minutes After emulsification, cooling to room temperature and preparing a water-in-oil type (W / O type) complex nanoliposome through high-pressure emulsification using a microfluidizer to permeate 3 to 5 times under 900 to 1,100 Bar conditions; and
(D) 상기 (C)단계에서 제조된 유중수형(W/O형) 복합나노리포좀을 상기 (A) 단계의 수상부에서 활성성분이 제거된 수상부, 상기 (B) 단계의 유상부와 다시 혼합하고 50 내지 60℃에서 4,000 내지 5,000 rpm으로 10 내지 30분 동안 호모믹서를 이용하여 유화하여 다중 유화형(W/O/W형) 복합나노리포좀 유화액을 제조하는 단계를 포함하여 제조될 수 있다.(D) The water-in-oil type (W/O type) complex nanoliposome prepared in step (C) is mixed again with the water phase part from which the active ingredient is removed from the water phase part of step (A) and the oil phase part of step (B). and emulsifying using a homomixer at 50 to 60 ° C. at 4,000 to 5,000 rpm for 10 to 30 minutes to prepare a multi-emulsion type (W / O / W type) complex nanoliposome emulsion.
상기 (D)단계에서 유중수형(W/O형) 복합나노리포좀은 복합나노리포좀 유화액 전체 중량에 대하여 10~20 중량%의 비율로 포함될 수 있다.In the step (D), the water-in-oil (W/O type) complex nanoliposome may be included in an amount of 10 to 20% by weight based on the total weight of the complex nanoliposome emulsion.
상기 펩타이드 혼합물은 단백질을 이루는 구성단위인 아미노산이 2개 내지 30개 미만으로 구성된 것의 혼합물을 말하며, 예를 들어, 휴먼올리고 펩타이드-1, 알에이치-폴리펩타이드-1, 아세틸헥사펩타이드-8, 카퍼트리펩타이드-1, 팔미토일트리펩타이드-5 및 카페오일트리펩타이드-1로 이루어지는 군으로부터 선택되는 어느 하나 이상이 사용될 수 있다.The peptide mixture refers to a mixture of 2 to less than 30 amino acids, which are structural units constituting a protein, and includes, for example, human oligopeptide-1, RH-polypeptide-1, acetylhexapeptide-8, copper At least one selected from the group consisting of tripeptide-1, palmitoyl tripeptide-5, and caffeoyl tripeptide-1 may be used.
상기 연어정소단백질추출물은 연어의 정소단백질로부터 유래한 추출물로서, 핵산 및 단백질을 다량 함유하고 있다.The salmon testis protein extract is an extract derived from salmon testis protein and contains a large amount of nucleic acid and protein.
상기 인지질(phospholipid)은 인산의 에스테르 화합물로서, 천연인지질 및 합성인지질을 포함하며, 포화(saturated) 타입 및 불포화(unsaturated) 타입 모두 사용 가능하며, 바람직하게는, 탄소수 12-30개인 지방산 사슬을 갖는 인지질류를 포함한다. 예를 들어, 상기 인지질은 포스파티딜콜린(Phosphatidylcholine, PC; 천연 또는 합성 레시틴), 디팔미토일포스파티딜콜린, 포스파티딕애씨드(Phosphatidic acid, PA), 리소포스파티딜콜린(Lysophosphatidylcholine, LPC), 포스파티딜세린(Phosphatidylserin, PS), 포스파티딜에탄올아민(Phosphatidylethanolamine, PE), 포스파티딜글리세롤(Phosphatidylglycerol, PG) 및 포스파티딜이노시톨(Phosphatidylinositol, PI)로 이루어진 군에서 선택된 어느 하나 이상이 사용될 수 있다.The phospholipid is an ester compound of phosphoric acid, and includes natural phospholipids and synthetic phospholipids, and both saturated and unsaturated types can be used, preferably having a fatty acid chain having 12 to 30 carbon atoms. Contains phospholipids. For example, the phospholipids include phosphatidylcholine (PC; natural or synthetic lecithin), dipalmitoylphosphatidylcholine, phosphatidic acid (PA), lysophosphatidylcholine (LPC), phosphatidylserin (PS) At least one selected from the group consisting of phosphatidylethanolamine (PE), phosphatidylglycerol (PG), and phosphatidylinositol (PI) may be used.
상기 동백오일은 동백의 씨로부터 추출된 오일일 수 있다.The camellia oil may be oil extracted from camellia seeds.
상기 지방산은 탄소수 10 내지 24를 갖는 포화 지방산 또는 1개 이상의 불포화 결합인 탄소 사슬을 갖는 불포화 지방산으로서, 예를 들어, 상기 지방산은 리놀레산, 올레산, 라우르산, 팔미트산, 카프릭산, 헵타데칸산, 펜타데칸산, 아라키드산, 아라키돈산 및 에루스산으로 이루어진 군에서 선택된 어느 하나 이상이 사용될 수 있다.The fatty acid is a saturated fatty acid having 10 to 24 carbon atoms or an unsaturated fatty acid having a carbon chain that is one or more unsaturated bonds. For example, the fatty acid is linoleic acid, oleic acid, lauric acid, palmitic acid, capric acid, hepta At least one selected from the group consisting of decanoic acid, pentadecanoic acid, arachidic acid, arachidonic acid and erucic acid may be used.
상기 세라마이드(ceramide)는 스핑고신과 지방산으로 이루어진 화합물을 말하고, N-아실스핀고신(Nacylsphingosine)이라고도 한다. 상기 세라마이드는 피부의 표피층의 각질층의 주성분으로, 예를 들어, 상기 세라마이드는 세라마이드 EOP, 세라마이드 NS, 세라마이드 NP, 세라마이드 AS, 및 세라마이드 AP로 이루어진 군으로부터 선택된 하나 이상을 포함할 수 있다. 상기 세라마이드는 일 양상의 나노에멀젼의 입자벽에서 인지질 사이를 메꾸어 주고, 나노에멀젼의 단단한 입자벽을 만들어줄 수 있다.The ceramide refers to a compound composed of sphingosine and fatty acids, and is also referred to as N-acylsphingosine. The ceramide is a main component of the stratum corneum of the epidermal layer of the skin. For example, the ceramide may include at least one selected from the group consisting of ceramide EOP, ceramide NS, ceramide NP, ceramide AS, and ceramide AP. The ceramide can fill between phospholipids in the particle walls of one aspect of the nanoemulsion and make the particle walls of the nanoemulsion hard.
상기 마카다미아 오일은 마카다미아로부터 오일을 추출하여 제조될 수 있는데, 상기 마카다미아의 열매는 75%의 천연식용유지와 9%의 단백질, 9%의 탄수화물과 2%의 식이섬유로 이루어져 있고, 나머지는 인체 영양에 필수요소인 칼슘, 인, 나트륨, 비타민 E, B1, B2, 나이아신, 철 등이 들어 있으며, 항암 외에 에이즈 발병 지연과 어린이 성장 촉진 등 효과가 있다고 알려진 체내 필수 미량원소인 셀레늄(Selenium)이 함유되어 있다.The macadamia oil can be prepared by extracting oil from macadamia nuts. The macadamia fruit is composed of 75% of natural edible oil, 9% of protein, 9% of carbohydrates and 2% of dietary fiber, and the rest is human nutrition It contains calcium, phosphorus, sodium, vitamins E, B1, B2, niacin, iron, etc., which are essential elements in the body, and contains selenium, an essential trace element in the body known to be effective in delaying the onset of AIDS and promoting growth in children, in addition to anticancer. has been
상기 마카다미아에 함유된 비타민과 불포화 지방산은 건조한 피부에 피부 윤기를 더해주고, 혈액 순환을 도와 피부 세포의 활력을 높여준다. 또한 불포화 지방산과 단백질, 미네랄의 함유로 활성산소로부터 피부를 보호하여주고 노화방지 효과를 가지고 있어 매끄럽고 건강한 피부 유지에 도움을 준다.The vitamins and unsaturated fatty acids contained in the macadamia add moisture to dry skin, help blood circulation, and increase the vitality of skin cells. In addition, it contains unsaturated fatty acids, proteins, and minerals to protect the skin from active oxygen and has an anti-aging effect, helping to maintain smooth and healthy skin.
상기 모링가씨 오일은 모링가씨(Moringa Seed)로부터 오일을 추출하여 제조될 수 있는데, 상기 모링가씨(Moringa Seed)는 모링가 나무의 씨앗으로서, 모링가 나무는 모링가과(Moringaceae Family), 모링가속(Moringa Genus)의 식물로서 학명은 Moringa Oleifera(이명 Moringa Pterygosperma)이며, 학명이 유래한 타밀어로는 Murunggai라고도 한다. 모링가는 콩과식물로 나뭇잎과 열매는 물론 나무전체를 식용으로 하는 열대성 나무이며, 다량의 아미노산, 무기질, 비타민 등 90가지 이상의 영양소를 함유하고 있다.The Moringa seed oil can be prepared by extracting oil from Moringa Seed. The Moringa Seed is a seed of the Moringa tree, and the Moringa tree belongs to the Moringaceae Family, As a plant of the Moringa genus, its scientific name is Moringa Oleifera (another name Moringa Pterygosperma), and it is also called Murunggai in Tamil, where the scientific name was derived. Moringa is a leguminous plant, a tropical tree whose leaves and fruits as well as the whole tree are edible, and contains more than 90 nutrients such as a large amount of amino acids, minerals, and vitamins.
특히, 모링가씨에 포함되어 있는 수용성 단백질은 물에 있는 오염물질을 정화해 주는 역할을 한다. 이 수용성 단백질들이 피부에 적용될 경우 피부에 있는 오염물질을 정화하여 피부를 깨끗하게 해 주는 디톡스 효능을 나타낸다. 또한, 베타카로틴, 루틴 등의 카로티노이드 성분, 비타민 및 무기질 성분을 다량 포함하고 있어 칙칙한 피부를 환하게 개선시켜 미백 효과를 구현할 수 있다.In particular, the water-soluble protein contained in Moringa seeds plays a role in purifying pollutants in water. When these water-soluble proteins are applied to the skin, they show a detoxifying effect that cleanses the skin by purifying pollutants on the skin. In addition, since it contains a large amount of carotenoid components such as beta-carotene and rutin, and vitamins and minerals, it can brighten dull skin and realize a whitening effect.
상기 흑솔잎발효추출액은 솔잎을 이용하여 제조될 수 있는데, 상기 솔잎은 소나무(Pinus densiflora Siebold et Zuccarini)의 잎으로 한국, 중국, 일본으로 동북아시아 지역으로 우리 민족과 오랜 역사를 같이한 나무의 잎과 새순이다. 신선한 솔잎에는 다량의 아스코르빈산과 비타민 A, B, K, 쓴맛을 내는 고미성 물질, 플라보노이드, 안토시안, 7 내지 12%의 수지(송진) 5% 정도의 타닌질, 탄수화물, 정유(精油) 등이 함유되어 있다.The black pine needle fermented extract can be prepared using pine needles. The pine needles are the leaves of pine trees (Pinus densiflora Siebold et Zuccarini), and the leaves of trees with a long history in Korea, China, and Japan in Northeast Asia. and new order Fresh pine needles contain a large amount of ascorbic acid, vitamins A, B, K, bitter substances, flavonoids, anthocyanins, 7 to 12% of resin (rosin), 5% of tannins, carbohydrates, essential oil, etc. contains this.
이밖에 소나무 전체에는 알코올, 에스테르 등 체내의 노폐물을 배출시키고 신진 대사를 촉진하는 성분, 페놀 화합물, 키니, 테르펜틴, 비타민 A, C, 클로로틸을 주성분으로 하는 성분과 글리코기닌, 아피에틴산도 있고, 철분도 풍부하고 적송 잎에 함유된 아미노산은 24종이고, 단백질로 구성된 아미노산 19종류도 확인되었다.In addition, the whole pine tree contains components that discharge wastes from the body such as alcohol and esters and promote metabolism, phenolic compounds, quinine, terpentine, vitamins A, C, and chlorotyl as main components, as well as glycoginin and apietic acid. It is also rich in iron, and 24 kinds of amino acids contained in the leaves of red pine, and 19 kinds of amino acids composed of proteins were also confirmed.
상기 솔잎은 비타민 C의 원료이며 공급원으로, 솔잎은 훨씬 짙은 녹색을 품고 있어서 풍부한 카로틴을 섭취할 수 있다. 솔잎의 경우, 약리학적 가치는 테르펜, 페놀 화합물, 타닌 등이 가진 일반 효과를 말할 수 있다. 이 밖에도 고혈압, 중풍, 당뇨, 치매 및 노화방지, 항암효과, 간과 위, 변비와 빈혈, 만성 알코올 중독 및 숙취해소, 니코틴제거, 피부미용과 체질개선 다이어트 남성들의 스태미나 각종 스트레스와 과다한 흡연, 음주로 머리가 무겁고 눈이 침침할 때 특히 머리를 맑게 하여 공부하는 학생이나 수험생들에게 좋다.The pine needles are a raw material and source of vitamin C, and the pine needles have a much darker green color, so rich carotene can be consumed. In the case of pine needles, the pharmacological value can refer to the general effects of terpenes, phenolic compounds, and tannins. In addition, high blood pressure, stroke, diabetes, dementia and aging prevention, anticancer effect, liver and stomach, constipation and anemia, chronic alcoholism and hangover relief, nicotine removal, skin care and constitution improvement, diet men's stamina, various stresses, excessive smoking and drinking When your head is heavy and your eyes are blurry, it is especially good for students or examinees who are studying by clearing their heads.
상기 흑솔잎발효추출액은 하기의 방법으로 제조된 흑솔잎발효추출액이 사용될 수 있다.The black pine leaf fermentation extract prepared by the following method may be used.
상기 흑솔잎발효추출액을 제조하기 위하여, 먼저, 솔잎을 준비한 후 정제수로 세척할 수 있다.In order to prepare the black pine needle fermented extract, first, pine needles may be prepared and then washed with purified water.
상기 단계는 솔잎을 준비한 후 20 내지 30℃ 온도의 정제수에서 세척함으로써 상기 솔잎에 부착되어 있는 먼지나 이물질 등을 제거할 수 있는데, 상기 준비되는 솔잎은 솔잎 새순을 포함하는 솔잎일 수 있다.In the above step, dust or foreign substances attached to the pine needles can be removed by preparing the pine needles and then washing them in purified water at a temperature of 20 to 30 ° C. The prepared pine needles may be pine needles containing pine needle sprouts.
다음으로, 상기 세척된 솔잎을 쌀뜨물에 침지시킬 수 있다.Next, the washed pine needles may be immersed in rice water.
상기 단계에서는 상기 세척된 솔잎을 쌀뜨물에 침지시킴으로써 상기 솔잎에 잔류하는 송진을 제거할 수 있는데, 상기 세척된 솔잎 전체 100 중량부에 대해, 쌀뜨물 400 내지 600 중량부의 중량 비율로 혼합하여 침지한 후 8 내지 12℃의 온도에서 2 내지 4일 동안 유지함으로써 진행될 수 있다.In the above step, the rosin remaining in the pine needles can be removed by immersing the washed pine needles in rice water, and 400 to 600 parts by weight of rice water is mixed and immersed in a weight ratio of 400 to 600 parts by weight with respect to 100 parts by weight of the total washed pine needles. After that, it may proceed by maintaining for 2 to 4 days at a temperature of 8 to 12 ° C.
그 다음으로, 상기 쌀뜨물에 침지된 솔잎을 분리한 후 건조할 수 있다.Next, the pine needles immersed in the rice water may be separated and then dried.
상기 단계에서는 상기 쌀뜨물에 침지된 솔잎을 분리한 후 20 내지 30℃의 온도에서 20 내지 40시간 동안 건조함으로써 진행될 수 있다.In the above step, the pine needles immersed in the rice water may be separated and then dried at a temperature of 20 to 30 ° C. for 20 to 40 hours.
이어서, 상기 건조된 솔잎을 증숙하여 흑솔잎을 제조할 수 있다.Subsequently, black pine needles can be prepared by steaming the dried pine needles.
상기 단계에서 상기 흑솔잎은 상기 건조된 솔잎을 75 내지 80℃ 온도에서 5 내지 7일 동안 수증기로 증숙함으로써 제조될 수 있다.In the above step, the black pine needles may be prepared by steaming the dried pine needles at a temperature of 75 to 80 ° C. for 5 to 7 days.
다음으로, 상기 증숙된 흑솔잎과 효모균 배양액을 혼합한 후 발효하여 흑솔잎발효액을 제조할 수 있다.Next, after mixing the steamed black pine needles and the yeast culture solution, a fermented black pine needle solution may be prepared by fermentation.
상기 단계에서는 상기 증숙된 흑솔잎 100 중량부에 대해, 효모균 배양액 10 내지 20 중량부의 중량 비율로 혼합한 후 43 내지 47℃의 온도에서 5 내지 7일 동안 발효시켜 흑솔잎발효액을 제조할 수 있다.In the above step, 10 to 20 parts by weight of the yeast culture solution is mixed in a weight ratio with respect to 100 parts by weight of the steamed black pine needles, and then fermented at a temperature of 43 to 47 ° C. for 5 to 7 days to prepare a fermented black pine needle solution.
또한, 상기 효모균 배양액은, 모링가 추출 효모균(Saccharomyces spp.) 발효액이 이용될 수 있는데, 상기 모링가 추출 효모균(Saccharomyces spp.) 발효액은, 모링가(Moringa oleifera L.) 잎을 30 내지 40℃ 온도에서 5 내지 10일 동안 건조하여 얻은 건조 모링가 잎을 40배 부피의 증류수에 담궈 85 내지 87℃ 및 1.5Pa에서 추출한 후 50% 농축하고 이후 찌꺼기를 제거하여 모링가 추출액을 제조하며, 상기 모링가 추출액에 효모균(Saccharomyces spp.)을 5×1.06 ~ 10×1.06 CFU/mL의 농도로 접종하여 38 내지 42℃에서 30시간 동안 배양하고, 10,000 내지 15,000rpm에서 10~15분간 원심분리하여 상등액을 취하고 120 내지 140℃ 온도에서 30 내지 50분 동안 멸균하여 제조된 모링가 추출 효모균 발효액이 사용될 수 있다.In addition, the yeast culture solution may be a Moringa extract yeast ( Saccharomyces spp. ) fermentation broth, the Moringa extract yeast ( Saccharomyces spp. ) fermentation broth, Moringa ( Moringa oleifera L. ) leaves at 30 to 40 ℃ Dried Moringa leaves obtained by drying for 5 to 10 days at temperature are immersed in 40 times the volume of distilled water, extracted at 85 to 87 ° C and 1.5 Pa, concentrated by 50%, and then the residue is removed to prepare a Moringa extract. Yeast ( Saccharomyces spp. ) was inoculated into the Ringa extract at a concentration of 5 × 1.0 6 ~ 10 × 1.0 6 CFU / mL, incubated at 38 to 42 ° C for 30 hours, and centrifuged at 10,000 to 15,000 rpm for 10 to 15 minutes Moringa extract yeast fermentation broth prepared by taking the supernatant and sterilizing it at 120 to 140 ° C. for 30 to 50 minutes may be used.
그 다음으로, 상기 흑솔잎발효액을 추출하여 흑솔잎발효추출액을 제조할 수 있다.Next, a black pine needle fermented extract can be prepared by extracting the black pine needle fermented liquid.
상기 단계에서 상기 흑솔잎발효액의 추출은 열수 추출법, 유기용매 추출법, 초음파 추출법, 초임계 추출법 등 다양한 추출법을 이용하여 수행될 수 있는데, 상기 추출의 구성은 공지의 기술인바, 설명의 편의 및 본 발명의 기술적 사상의 명확성을 위하여 이에 대한 구체적인 설명은 생략하기로 한다.In the above step, the extraction of the black pine needle fermented liquid may be performed using various extraction methods such as hot water extraction, organic solvent extraction, ultrasonic extraction, and supercritical extraction. For clarity of the technical idea of , a detailed description thereof will be omitted.
이하, 첨부된 도면을 참조하여 본 발명의 기술적 사상의 일 실시예에 따른 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물에 대한 실시예를 들어 더욱 구체적으로 설명하기로 한다.Hereinafter, with reference to the accompanying drawings, an example of a cosmetic composition having UV protection and whitening and wrinkle improvement effects according to an embodiment of the technical idea of the present invention will be described in more detail.
< 실시예 1 ><Example 1>
징크옥사이드 3 중량%, 나이아신아마이드 3.5 중량%, 아데노신 0.04 중량%, 불가리스 쑥 오일 4 중량%, 복합나노리포좀 2 중량%, 마카다미아 오일 1.5 중량%, 모링가씨 오일 1.5 중량%, 흑솔잎발효추출액 0.5 중량%, 에탄올 10 중량%, 1,2-헥산디올 2 중량%, 병풀추출물 0.5 중량%, 알란토인 0.25 중량%, 에틸헥실글리세린 2 중량%, 글리세릴카프릴레이트 0.5 중량% 및 잔량의 정제수를 혼합하여 화장료 조성물을 제조하였다.
이때, 상기 복합나노리포좀은 (A) 수상부 및 유상부의 전체 중량에 대하여, 펩타이드 혼합물 5 중량부, 에틸헥실글리세린 10 중량부, 연어정소단백질추출물 5 중량부, 베헤닐알코올(Behenyl Alcohol) 5 중량부, 1,2-부틸렌글리콜 15 중량부, 판테닐트라이아세테이트(Panthenyl Triacetate) 5 중량부 및 이세티오네이트 0.5 중량부를 정제수 50 중량부와 65℃ 온도에서 혼합하여 수상부를 제조하는 단계; (B) 수상부 및 유상부의 전체 중량에 대하여, 인지질 15 중량부, 디메치콘 10 중량부, 동백오일 7 중량부, 지방산 1 중량부, 콜레스테롤 1.5 중량부, 세라마이드복합체 5 중량부, 레시틴(Hydrogenated Lecithin) 3 중량부 및 소듐메틸코코일타우레이트 0.5 중량부를 65℃ 온도에서 혼합하여 유상부를 제조하는 단계; (C) 상기 (A)단계에서 제조된 수상부를 55℃ 온도에서 가온한 후, 상기 (B) 단계에서 제조된 유상부를 첨가하여 4,500 rpm으로 30분 동안 호모믹서를 이용하여 유화시킨 뒤, 상온으로 냉각하여 마이크로플루이다이저(Microfluidizer)를 이용하여 1,000 Bar 조건에서 4회 투과시키는 고압 유화를 통하여 유중수형(W/O형) 복합나노리포좀을 제조하는 단계; 및 (D) 상기 (C)단계에서 제조된 유중수형(W/O형) 복합나노리포좀을 상기 (A) 단계의 수상부에서 활성성분이 제거된 수상부, 상기 (B) 단계의 유상부와 다시 혼합하고 55℃에서 4,500 rpm으로 20분 동안 호모믹서를 이용하여 유화하여 다중 유화형(W/O/W형) 복합나노리포좀 유화액을 제조하는 단계를 포함하여 제조되었고, 상기 (D)단계에서 유중수형(W/O형) 복합나노리포좀은 복합나노리포좀 유화액 전체 중량에 대하여 15 중량%의 비율로 포함되었다.At this time, the complex nano-liposome is (A) 5 parts by weight of the peptide mixture, 10 parts by weight of ethylhexyl glycerin, 5 parts by weight of salmon testis protein extract, 5 parts by weight of behenyl alcohol, based on the total weight of the water phase and the oil phase Preparing an aqueous phase by mixing 15 parts by weight of 1,2-butylene glycol, 5 parts by weight of Panthenyl Triacetate and 0.5 parts by weight of isethionate with 50 parts by weight of purified water at 65 ° C; (B) 15 parts by weight of phospholipid, 10 parts by weight of dimethicone, 7 parts by weight of camellia oil, 1 part by weight of fatty acid, 1.5 parts by weight of cholesterol, 5 parts by weight of ceramide complex, lecithin (Hydrogenated Lecithin) ) preparing an oil phase by mixing 3 parts by weight and 0.5 parts by weight of sodium methyl cocoyl taurate at a temperature of 65 ° C; (C) After warming the water phase prepared in step (A) at a temperature of 55 ° C, adding the oily phase prepared in step (B) and emulsifying using a homomixer at 4,500 rpm for 30 minutes, then returning to room temperature Preparing a water-in-oil type (W / O type) complex nanoliposome through high-pressure emulsification by cooling and permeating 4 times under 1,000 Bar conditions using a microfluidizer; And (D) the water-in-oil type (W / O type) complex nanoliposome prepared in step (C) is mixed with the water phase part in which the active ingredient is removed from the water phase part in step (A), and the oil phase part in step (B). It was prepared by mixing and emulsifying using a homomixer at 55 ° C. at 4,500 rpm for 20 minutes to prepare a multi-emulsion type (W / O / W type) complex nanoliposome emulsion. The water type (W/O type) complex nanoliposome was included in an amount of 15% by weight based on the total weight of the complex nanoliposome emulsion.
< 실시예 2 ><Example 2>
실시예 1과 동일한 조성물을 이용하여 화장료 조성물을 제조하였는데, 실시예 2에서는 징크옥사이드 4 중량%, 나이아신아마이드 2.5 중량%, 아데노신 0.02 중량%, 불가리스 쑥 오일 5 중량%, 복합나노리포좀 2.5 중량%, 마카다미아 오일 1 중량%, 모링가씨 오일 2 중량%, 흑솔잎발효추출액 0.4 중량%, 에탄올 11 중량%, 1,2-헥산디올 1.5 중량%, 병풀추출물 0.9 중량%, 알란토인 0.2 중량%, 에틸헥실글리세린 1.5 중량%, 글리세릴카프릴레이트 0.2 중량% 및 잔량의 정제수를 혼합하여 화장료 조성물을 제조하였다.A cosmetic composition was prepared using the same composition as in Example 1. In Example 2, 4% by weight of zinc oxide, 2.5% by weight of niacinamide, 0.02% by weight of adenosine, 5% by weight of vulgaris mugwort oil, 2.5% by weight of complex nanoliposomes,
< 실시예 3 ><Example 3>
실시예 1과 동일한 조성물을 이용하여 화장료 조성물을 제조하였는데, 실시예 3에서는 징크옥사이드 2 중량%, 나이아신아마이드 4.5 중량%, 아데노신 0.8 중량%, 불가리스 쑥 오일 3 중량%, 복합나노리포좀 1.5 중량%, 마카다미아 오일 2 중량%, 모링가씨 오일 1 중량%, 흑솔잎발효추출액 0.6 중량%, 에탄올 9 중량%, 1,2-헥산디올 2.5 중량%, 병풀추출물 0.3 중량%, 알란토인 0.3 중량%, 에틸헥실글리세린 2.5 중량%, 글리세릴카프릴레이트 0.8 중량% 및 잔량의 정제수를 혼합하여 화장료 조성물을 제조하였다.A cosmetic composition was prepared using the same composition as in Example 1. In Example 3, 2% by weight of zinc oxide, 4.5% by weight of niacinamide, 0.8% by weight of adenosine, 3% by weight of vulgaris mugwort oil, 1.5% by weight of complex nanoliposomes,
< 비교예 1 ><Comparative Example 1>
불가리스 쑥 오일 4 중량%, 마카다미아 오일 1.5 중량%, 모링가씨 오일 1.5 중량%, 흑솔잎발효추출액 0.5 중량%, 에탄올 10 중량%, 1,2-헥산디올 2 중량%, 병풀추출물 0.5 중량%, 알란토인 0.25 중량%, 에틸헥실글리세린 2 중량%, 글리세릴카프릴레이트 0.5 중량% 및 잔량의 정제수를 혼합하여 화장료 조성물을 제조하였다.4% by weight of bulgaris mugwort oil, 1.5% by weight of macadamia oil, 1.5% by weight of moringa seed oil, 0.5% by weight of fermented extract of black pine needles, 10% by weight of ethanol, 2% by weight of 1,2-hexanediol, 0.5% by weight of centella asiatica extract, A cosmetic composition was prepared by mixing 0.25% by weight of allantoin, 2% by weight of ethylhexyl glycerin, 0.5% by weight of glyceryl caprylate, and the remaining amount of purified water.
< 비교예 2 ><Comparative Example 2>
징크옥사이드 3 중량%, 복합나노리포좀 2 중량%, 마카다미아 오일 1.5 중량%, 모링가씨 오일 1.5 중량%, 에탄올 10 중량%, 1,2-헥산디올 2 중량%, 병풀추출물 0.5 중량%, 알란토인 0.25 중량%, 에틸헥실글리세린 2 중량%, 글리세릴카프릴레이트 0.5 중량% 및 잔량의 정제수를 혼합하여 화장료 조성물을 제조하였다.
1. 피부 밝기 개선 평가1. Evaluation of skin brightness improvement
실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물의 피부 밝기 개선 효과를 평가하였다.The cosmetic compositions according to Examples 1, 2 and 3 and the cosmetic compositions according to Comparative Examples 1 and 2 were evaluated for their skin brightness improvement effects.
도 1은 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물의 피부 밝기 개선 효과를 보여주는 그래프이다.1 is a graph showing the skin brightness improvement effect of the cosmetic compositions according to Examples 1, 2 and 3 and the cosmetic compositions according to Comparative Examples 1 and 2.
상기 피부 밝기 개선 효과는 20~40세의 여성 중 선정된 35명에 대하여 Chromameter CR-400을 이용하여 시험 대상자의 사용 전 피부 밝기를 측정한 후, 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물을 개별적으로 사용하여 피부 밝기를 재측정 하였다.The skin brightness improvement effect was measured by using Chromameter CR-400 for 35 selected women between the ages of 20 and 40, and then measuring the skin brightness before use, and then using the cosmetic composition according to Examples 1, 2, and 3 , Skin brightness was remeasured using the cosmetic compositions according to Comparative Examples 1 and 2 individually.
상기 측정 결과는 하기의 [표 1] 및 도 1에 나타내었으며, 측정값은 L*의 최대값과 최소값을 제외한 3회의 평균값으로 나타내었다.The measurement results are shown in [Table 1] and FIG. 1 below, and the measured values are shown as the average value of three times excluding the maximum and minimum values of L*.
상기 [표 1] 및 도 1을 참조하면, 실시예 1, 2, 3에 따른 화장료 조성물이 비교예 1, 2에 따른 화장료 조성물에 비해 피부 밝기가 현저히 개선된 것을 확인할 수 있다.Referring to [Table 1] and FIG. 1, it can be confirmed that the skin brightness of the cosmetic compositions according to Examples 1, 2, and 3 was significantly improved compared to the cosmetic compositions according to Comparative Examples 1 and 2.
2. 피부 주름 개선 효과 평가2. Evaluation of skin wrinkle improvement effect
실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물의 피부 주름 개선 효과를 평가하였다.Skin wrinkle improvement effects of the cosmetic compositions according to Examples 1, 2 and 3 and the cosmetic compositions according to Comparative Examples 1 and 2 were evaluated.
도 2는 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1 내지 4에 따른 화장료 조성물의 피부 주름 개선 효과를 보여주는 그래프이다.Figure 2 is a graph showing the skin wrinkle improvement effect of the cosmetic compositions according to Examples 1, 2, and 3 and the cosmetic compositions according to Comparative Examples 1 to 4.
상기 피부 주름 개선 효과는 30세 이상 여성 50명을 대상으로 피부 주름개선을 측정하였다.The skin wrinkle improvement effect was measured for skin wrinkle improvement in 50 women aged 30 years or older.
상기 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물을 눈가를 중심으로 하루에 2회씩(아침 및 저녁) 10주간 도포하였고, 피부 주름개선 측정기 ANTERA 3D를 이용하여 피험자의 피부 주름 개선 효과를 측정하였다.The cosmetic compositions according to Examples 1, 2, and 3 and the cosmetic compositions according to Comparative Examples 1 and 2 were applied around the eyes twice a day (morning and evening) for 10 weeks, using an ANTERA 3D skin wrinkle improvement measuring instrument The skin wrinkle improvement effect of the subject was measured.
시험 결과는 측정기의 A1(A1(10주)-A1(0주)) 값으로 기재하였다. 상기 A1 값은 피부 주름점탄성의 성질을 나타내며, 결과는 하기 [표 2] 및 도 2에 나타낸 바와 같다.The test results were described as A1 (A1 (10 weeks) - A1 (0 weeks)) value of the measuring instrument. The A1 value represents the property of skin wrinkle viscoelasticity, and the results are shown in [Table 2] and FIG. 2 below.
상기 [표 2] 및 도 2를 참조하면, 실시예 1, 2, 3에 따른 화장료 조성물이 비교예 1, 2에 따른 화장료 조성물에 비해 피부 주름 개선 효과가 현저히 우수한 것을 확인할 수 있다.Referring to [Table 2] and FIG. 2, it can be confirmed that the cosmetic compositions according to Examples 1, 2 and 3 have significantly better skin wrinkle improvement effects than the cosmetic compositions according to Comparative Examples 1 and 2.
3. 은폐율 측정3. Measure the concealment rate
상기 화장료 조성물의 자외선 차단 효과를 알아보기 위하여 반드시 고려해야 할 부분이 바로 백탁도이다. 백탁도를 확인하기 위하여 실시예 1, 2, 3에 따른 화장료 조성물과, 비교예 1, 2에 따른 화장료 조성물의 은폐율을 측정하여 하기의 [표 3]에 기재하였다. 상기 은폐율은 아래 수학식 1을 이용하여 산출하였으며, 1에 가까울수록 은폐율(=백탁도, 커버력)이 높다.In order to find out the UV blocking effect of the cosmetic composition, the part that must be considered is the cloudiness. In order to confirm the cloudiness, the coverage of the cosmetic compositions according to Examples 1, 2 and 3 and the cosmetic compositions according to Comparative Examples 1 and 2 were measured and described in [Table 3] below. The concealment ratio was calculated using
은폐율은 흑백지에 도막 형성용 어플리케이터로 실시예 1, 2, 3에 따른 화장료와, 비교예 1, 2에 따른 화장료를 동일한 양을 올려 도막을 형성하고 1시간 건조 후 색차계(Coloremeter NR-60CP)로 측정하였다.The concealment rate was measured by applying the same amount of cosmetics according to Examples 1, 2 and 3 and cosmetics according to Comparative Examples 1 and 2 with an applicator for forming a coating film on black and white paper to form a coating film, drying for 1 hour, and then using a colorimeter (Coloremeter NR-60CP). ) was measured.
[수학식 1][Equation 1]
상기 [표 3]을 참조하면, 은폐율 측정 결과, 실시예 1, 2, 3에 따른 화장료 조성물의 은폐율이, 비교예 1, 2에 따른 화장료 조성물보다 우수한 것을 확인할 수 있다.Referring to [Table 3], as a result of measuring the coverage, it can be confirmed that the coverage of the cosmetic composition according to Examples 1, 2 and 3 is superior to the cosmetic composition according to Comparative Examples 1 and 2.
4. 미백 개선에 대한 실험4. Experiments on whitening improvement
멜라닌 색소는 기미나 검버섯 등 피부노화 현상의 주된 원인으로, 티로시네이즈는 멜라닌 색소를 생성하는 주요 효소인데, 실시예 1에 따른 화장료 조성물의 미백효과를 확인하기 위해 멜라닌 합성의 주요 효소인 티로시네이즈로 생긴 DOPA( dihydroxyphenylalanine) 또는 dopachrome 생성량을 비교하여 시험물질의 효소활성 억제능을 측정하였다.Melanin pigment is the main cause of skin aging phenomena such as freckles and age spots, and tyrosinase is a major enzyme that generates melanin pigment. The enzyme activity inhibitory ability of the test substance was measured by comparing the amount of DOPA (dihydroxyphenylalanine) or dopachrome produced by Naze.
시험방법은 tyrosine을 기질로 사용하여 효소 반응액에 넣어 일정시간 반응시킨 후 반응생성물인 dopachrome의 흡수파장인 475nm에서 흡광도를 측정하였다.The test method used tyrosine as a substrate, put it into the enzyme reaction solution, reacted for a certain time, and measured the absorbance at 475 nm, which is the absorption wavelength of the reaction product, dopachrome.
0.1M Potassium phosphate buffer solution(pH 6.8) 500㎕에 L-tyrosine (0.3㎎/㎖) 500㎕와 실시예 1 및 비교예 1에 따른 화장료를 각각 450㎕를 넣고 37℃ 수욕 상에서 10분간 반응시킨 후 신속하게 냉장고에서 5분간 방치하여 반응을 중단시킨다. tyrosinase(1,250 units/㎖) 50㎕를 넣어 10분간 incubation시킨 후, 475nm에서 흡광도를 측정하였다. Control은 검액 대신 시료 용매 450㎕를 넣는다. 색 보정인 Blank는 tyrosinase 대신 Potassium phosphate buffer solution (pH 6.8, 0.1 M)을 50㎕ 첨가하며, 실험군과 동일한 농도의 시료를 첨가하였다. 하기 수학식을 이용하여 티로시네이즈 저해 활성을 계산하여 [표 4]에 나타내었다.500 μl of L-tyrosine (0.3 mg/ml) and 450 μl of the cosmetics according to Example 1 and Comparative Example 1 were added to 500 μl of 0.1M Potassium phosphate buffer solution (pH 6.8), followed by reaction on a 37°C water bath for 10 minutes. The reaction is quenched by quickly placing in the refrigerator for 5 minutes. After adding 50 μl of tyrosinase (1,250 units/ml) and incubating for 10 minutes, absorbance was measured at 475 nm. As a control, 450 μl of the sample solvent is added instead of the test solution. For the color correction blank, 50 μl of potassium phosphate buffer solution (pH 6.8, 0.1 M) was added instead of tyrosinase, and a sample of the same concentration as the experimental group was added. Tyrosinase inhibitory activity was calculated using the following equation and shown in [Table 4].
% inhibition = [(A-B)/A] ⅹ 100% inhibition = [(A-B)/A] x 100
A: 시험시료(inhibitor)가 들어있지 않은 반응액(control)의 반응 후 흡광도A: Absorbance after reaction of a reaction solution (control) that does not contain a test sample (inhibitor)
B: 시험시료가 들어있는 반응액(reaction)의 반응 후 흡광도.B: Absorbance after reaction of the reaction solution containing the test sample.
상기 [표 4]를 참조하면, 실시예 1에 따른 화장료 조성물은 36.37%의 티로시네이즈 억제율을 보인 반면, 비교예 1에 따른 화장료 조성물은 티로시네이즈 억제율이 15.11%인 것을 확인할 수 있었다.Referring to [Table 4], it was confirmed that the cosmetic composition according to Example 1 showed a tyrosinase inhibition rate of 36.37%, whereas the cosmetic composition according to Comparative Example 1 had a tyrosinase inhibition rate of 15.11%.
또한, 실시예 1에 따른 화장료 조성물은 대조군인 Arbutin 보다 약간 작은 억제율을 나타내었다. 따라서 실시예 1에 따른 화장료 조성물은 티로시네이즈 억제에 효과가 있다고 할 수 있다.In addition, the cosmetic composition according to Example 1 showed a slightly smaller inhibition rate than the control group, Arbutin. Therefore, the cosmetic composition according to Example 1 can be said to be effective in inhibiting tyrosinase.
5. 보습 효과 측정5. Measurement of moisturizing effect
코르네오메타(Corneometer) CM820(독일 Courage)을 이용한 커패시턴스 측정법을 사용하고, 시료는 실시예 1에 따른 화장료 조성물과 비교예 1에 따른 화장료 조성물을 사용하여 보습 효과를 비교 측정하였다.A capacitance measurement method using a Corneometer CM820 (Courage, Germany) was used, and the moisturizing effect was compared and measured using the cosmetic composition according to Example 1 and the cosmetic composition according to Comparative Example 1 as samples.
20세 내지 50세의 여자 15명을 대상으로 하여, 시험 시작 직전 하박 내측면을 대상으로 항온항습실에서 20분 동안 적응하게 한 다음, 피부 수분을 일정하게 유지시켰다. 그 다음, 코르네오메타 C820을 사용하여 각 시료 도포부위의 초기 수분 보유양을 측정한 후, 실시예 1에 따른 화장료 조성물과 비교예 1에 따른 화장료 조성물을 도포하였다.15 women between the ages of 20 and 50 were allowed to adapt to the inner surface of the lower arm in a constant temperature and humidity room for 20 minutes just before the start of the test, and then the skin moisture was kept constant. Then, after measuring the initial moisture content of each sample application site using Corneometa C820, the cosmetic composition according to Example 1 and the cosmetic composition according to Comparative Example 1 were applied.
도포 20분 후에 수분증감율을 1차 측정하고, 2시간 후 다시 수분증감율을 측정하였다. 각 측정부위를 3번 반복 측정하고 그 평균값으로 하기 [수학식 2]에 따라 피부 수분 증감율을 계산하여 [표 5]에 나타내었다.After 20 minutes of application, the moisture change rate was first measured, and the moisture change rate was measured again after 2 hours. Each measurement site was repeatedly measured three times, and the skin moisture change rate was calculated according to the following [Equation 2] as the average value, and it is shown in [Table 5].
[수학식 2][Equation 2]
수분증감율(%) = (Tdi-Tdo)-(Ntdi-NTdo) / ((Ntdi-Ntdo) + Tdo) * 100Moisture change rate (%) = (Tdi-Tdo)-(Ntdi-NTdo) / ((Ntdi-Ntdo) + Tdo) * 100
Tdi : 시료 도포 부위의 n번째 측정값Tdi: nth measured value of the sample application area
Tdo : 시료 도포 전 측정값Tdo: measured value before sample application
Ntdi : 시료를 도포하지 않은 부위의 n번째 측정값Ntdi: nth measured value of the area where the sample is not applied
NTdo : 시료를 도포하지 않은 부위의 도포 전 측정값NTdo: measured value before application of the area where the sample was not applied
상기 [표 5]를 참조하면, 실시예 1에 따른 화장료 조성물이 비교예 1에 따른 화장료 조성물보다 초기뿐만 아니라 시간이 경과하여도 보습 효과가 우수함을 확인할 수 있었다.Referring to [Table 5], it was confirmed that the cosmetic composition according to Example 1 was superior to the cosmetic composition according to Comparative Example 1 in moisturizing effect not only in the initial stage but also over time.
이상, 본 발명의 바람직한 일 실시예를 설명하였지만, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 본 발명이 그 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 일 실시예는 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.Although the preferred embodiment of the present invention has been described above, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. You will be able to. Therefore, one embodiment described above should be understood as illustrative in all respects and not limiting.
Claims (6)
상기 징크옥사이드 1 내지 5 중량%, 나이아신아마이드 2 내지 5 중량%, 아데노신 0.01 내지 0.1 중량% 및 불가리스 쑥 오일 2 내지 6 중량%의 중량 비율로 포함되며,
상기 징크옥사이드, 나이아신아마이드, 아데노신, 불가리스 쑥 오일 이외에, 복합나노리포좀, 마카다미아 오일, 모링가씨 오일, 흑솔잎발효추출액, 에탄올, 1,2-헥산디올, 병풀추출물, 알란토인, 에틸헥실글리세린, 글리세릴카프릴레이트 및 정제수를 더 포함하는 것을 특징으로 하는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물.
Contains zinc oxide, niacinamide, adenosine and vulgaris mugwort oil as active ingredients,
1 to 5% by weight of the zinc oxide, 2 to 5% by weight of niacinamide, 0.01 to 0.1% by weight of adenosine, and 2 to 6% by weight of vulgaris mugwort oil,
In addition to the above zinc oxide, niacinamide, adenosine, and vulgaris mugwort oil, complex nanoliposomes, macadamia oil, moringa seed oil, black pine needle fermented extract, ethanol, 1,2-hexanediol, centella asiatica extract, allantoin, ethylhexylglycerin, glycerin A cosmetic composition having UV protection and whitening and anti-wrinkle effects, further comprising lycaprylate and purified water.
상기 징크옥사이드 1 내지 5 중량%, 나이아신아마이드 2 내지 5 중량%, 아데노신 0.01 내지 0.1 중량%, 불가리스 쑥 오일 2 내지 6 중량%, 복합나노리포좀 1 내지 3 중량%, 마카다미아 오일 0.5 내지 2.5 중량%, 모링가씨 오일 0.5 내지 2.5 중량%, 흑솔잎발효추출액 0.3 내지 0.7 중량%, 에탄올 8 내지 12 중량%, 1,2-헥산디올 1 내지 3 중량%, 병풀추출물 0.1 내지 1 중량%, 알란토인 0.15 내지 0.35 중량%, 에틸헥실글리세린 1 내지 3 중량%, 글리세릴카프릴레이트 0.1 내지 1 중량% 및 잔량의 정제수를 포함하는 것을 특징으로 하는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물.
According to claim 1,
1 to 5% by weight of the zinc oxide, 2 to 5% by weight of niacinamide, 0.01 to 0.1% by weight of adenosine, 2 to 6% by weight of vulgaris mugwort oil, 1 to 3% by weight of complex nanoliposomes, 0.5 to 2.5% by weight of macadamia oil, Moringa seed oil 0.5 to 2.5% by weight, black pine needle fermented extract 0.3 to 0.7% by weight, ethanol 8 to 12% by weight, 1,2-hexanediol 1 to 3% by weight, centella asiatica extract 0.1 to 1% by weight, allantoin 0.15 to 12% by weight 0.35% by weight, 1 to 3% by weight of ethylhexyl glycerin, 0.1 to 1% by weight of glyceryl caprylate and the remaining amount of purified water A cosmetic composition with UV protection and whitening and wrinkle improvement effects.
상기 복합나노리포좀은 연어정소단백질추출물과 동백오일을 포함하여 제조된 것을 특징으로 하는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물.
According to claim 4,
The composite nano-liposome is a cosmetic composition with UV protection and whitening and anti-wrinkle effects, characterized in that prepared by including salmon testis protein extract and camellia oil.
상기 징크옥사이드 3 중량%, 나이아신아마이드 3.5 중량%, 아데노신 0.04 중량%, 불가리스 쑥 오일 4 중량%, 복합나노리포좀 2 중량%, 마카다미아 오일 1.5 중량%, 모링가씨 오일 1.5 중량%, 흑솔잎발효추출액 0.5 중량%, 에탄올 10 중량%, 1,2-헥산디올 2 중량%, 병풀추출물 0.5 중량%, 알란토인 0.25 중량%, 에틸헥실글리세린 2 중량%, 글리세릴카프릴레이트 0.5 중량% 및 잔량의 정제수를 포함하는 것을 특징으로 하는 자외선 차단과 미백주름개선 효과가 있는 화장료 조성물.According to claim 5,
The zinc oxide 3% by weight, niacinamide 3.5% by weight, adenosine 0.04% by weight, vulgaris mugwort oil 4% by weight, complex nanoliposome 2% by weight, macadamia oil 1.5% by weight, moringa seed oil 1.5% by weight, black pine needle fermented extract 0.5% by weight, 10% by weight of ethanol, 2% by weight of 1,2-hexanediol, 0.5% by weight of centella asiatica extract, 0.25% by weight of allantoin, 2% by weight of ethylhexyl glycerin, 0.5% by weight of glyceryl caprylate and the remaining amount of purified water A cosmetic composition having UV protection and whitening and wrinkle improvement effects, characterized in that.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220120067A KR102469550B1 (en) | 2022-09-22 | 2022-09-22 | Cosmetic composition with uv protection, whitening and wrinkle improvement effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220120067A KR102469550B1 (en) | 2022-09-22 | 2022-09-22 | Cosmetic composition with uv protection, whitening and wrinkle improvement effects |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102469550B1 true KR102469550B1 (en) | 2022-11-22 |
Family
ID=84236628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220120067A Active KR102469550B1 (en) | 2022-09-22 | 2022-09-22 | Cosmetic composition with uv protection, whitening and wrinkle improvement effects |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102469550B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100966835B1 (en) | 2008-02-19 | 2010-06-29 | 장문식 | Cosmetic composition containing extracts of plant mixtures consisting of licorice, horse riding, sewage, black sesame seeds, situation mushrooms, donkeys, baekbaekpi, baekryeok, red ginseng, and gold having skin protection against ultraviolet rays and anti-wrinkle |
KR20120004021A (en) * | 2010-07-06 | 2012-01-12 | 원광대학교산학협력단 | Cosmetic composition for skin improvement comprising a ginseng culture root extract trapped in liposomes and a method for preparing the same |
KR101477891B1 (en) | 2013-02-20 | 2014-12-30 | 한울환경연구원(주) | A Composition of Platanus orientalis L extract for anti whitening, wrinkle, aging |
KR101773452B1 (en) * | 2017-03-20 | 2017-08-31 | 주식회사 더마랩 | Method for preparing fermented extraction of pine needle using steaming and drying process and cosmetic composition containing the same |
CN107847407A (en) * | 2015-07-22 | 2018-03-27 | 兰达拉伯斯(2012)有限公司 | UV protection components |
KR102052511B1 (en) | 2019-03-12 | 2019-12-05 | 임수복 | Perilla oil and Method for manufacturing the same |
-
2022
- 2022-09-22 KR KR1020220120067A patent/KR102469550B1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100966835B1 (en) | 2008-02-19 | 2010-06-29 | 장문식 | Cosmetic composition containing extracts of plant mixtures consisting of licorice, horse riding, sewage, black sesame seeds, situation mushrooms, donkeys, baekbaekpi, baekryeok, red ginseng, and gold having skin protection against ultraviolet rays and anti-wrinkle |
KR20120004021A (en) * | 2010-07-06 | 2012-01-12 | 원광대학교산학협력단 | Cosmetic composition for skin improvement comprising a ginseng culture root extract trapped in liposomes and a method for preparing the same |
KR101477891B1 (en) | 2013-02-20 | 2014-12-30 | 한울환경연구원(주) | A Composition of Platanus orientalis L extract for anti whitening, wrinkle, aging |
CN107847407A (en) * | 2015-07-22 | 2018-03-27 | 兰达拉伯斯(2012)有限公司 | UV protection components |
KR101773452B1 (en) * | 2017-03-20 | 2017-08-31 | 주식회사 더마랩 | Method for preparing fermented extraction of pine needle using steaming and drying process and cosmetic composition containing the same |
KR102052511B1 (en) | 2019-03-12 | 2019-12-05 | 임수복 | Perilla oil and Method for manufacturing the same |
Non-Patent Citations (2)
Title |
---|
Naver Blog, "Perfect Skin Ecoderma Pure Mild Cica Sun UV Sun Cream", 2021.08.21.* * |
네이버 블로그, "퍼펙트스킨 에코더마 퓨어마일드 시카선 자외선 썬크림", 2021.08.21.* |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8496948B2 (en) | Topical skin composition comprising mineral yeast ferments | |
KR101810231B1 (en) | Cosmetic composition for improving acne containing propolis spicule powder | |
KR102156898B1 (en) | Ingestible cosmetic composition for skin whitening, skin moisturizing, antioxidant, anti-inflammatory, skin barrier strengthening and skin absorption containing the lactic acid fermentation mixture | |
KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
KR101769419B1 (en) | Multifunctional nourishing cream composition and preparing method of the same | |
KR101716680B1 (en) | Shiunko fermented oil and producing method thereof | |
KR20210001260A (en) | Cosmetic compositions having Antioxidant effect comprising Phloretin, Fragaria Vesca (Strawberry) Leaf Extract and Leontopodium Alpinum Callus Culture Extract | |
KR20160123732A (en) | Cosmetic composition comprising the extract of cynara scolymus and brassica oleracea var. botrytis as active ingredient | |
KR101915655B1 (en) | Cosmetic composition containing Croton Lechleri resin extract | |
KR20100061881A (en) | Cosmetic composition for promoting desquamation | |
KR20120140141A (en) | Cosmetic composition comprising the fermented extracts and the extracts of the rice | |
KR101081910B1 (en) | Cosmetic composition with skin tone improvement and anti-aging effect containing kiwi extract | |
KR101744889B1 (en) | Composition for Anti-oxidation, Whitening and Wrinkles protection | |
US10980736B2 (en) | Coconut shell extracts, compositions containing same and uses | |
KR101456059B1 (en) | The cosmetic composition effective in whitening and anti-aging mainly comprised of roasted licorice extract | |
KR20230090952A (en) | Nanoliposomes containing inotodiol derived from chaga mushroom as an active ingredient, manufacturing method thereof and cosmetic composition containing the same | |
KR20170076147A (en) | Composition for improving skin | |
KR102130243B1 (en) | A cosmetic composition for skin whitening, anti-wrinkle, anti-aging, and anti-oxidation containing glutathione, natural spicule powder, acetyl hexapeptide and broussonetia kazinoki extract | |
KR102469550B1 (en) | Cosmetic composition with uv protection, whitening and wrinkle improvement effects | |
KR100864915B1 (en) | Composition containing as an active ingredient plum and catabolic extract with antioxidant | |
KR102446814B1 (en) | Cosmetic composition for preventing or improving spots | |
CN112972359B (en) | Cosmetic composition wrapped by microcapsules and application of cosmetic composition in hibiscus cream | |
KR102549572B1 (en) | Cosmetic composition comprising a complex composition of seed oil and salmon testis protein extract | |
AU2022253365A1 (en) | Ligustrum lucidum extract useful for the treatment and/or care of the skin | |
KR20130052288A (en) | Cosmetic composition comprising the hot spring water extract of nelumbo nucifera gaertner as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20220922 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20220923 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20220922 Patent event code: PA03021R01I Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221101 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20221115 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221117 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20221118 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |